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Summary
The purpose of this study was to analyze the possible effects of machine perfu-
sion (MP) versus cold storage (CS) on delayed graft function (DGF) and early
graft survival in expanded criteria donor kidneys (ECD). As part of the previ-
ously reported international randomized controlled trial 91 consecutive heart-
beating deceased ECDs – defined according to the United Network of Organ
Sharing definition – were included in the study. From each donor one kidney
was randomized to MP and the contralateral kidney to CS. All recipients were
followed for 1 year. The primary endpoint was DGF. Secondary endpoints
included primary nonfunction and graft survival. DGF occurred in 27 patients
in the CS group (29.7%) and in 20 patients in the MP group (22%). Using the
logistic regression model MP significantly reduced the risk of DGF compared
with CS (OR 0.460, P = 0.047). The incidence of nonfunction in the CS group
(12%) was four times higher than in the MP group (3%) (P = 0.04). One-year
graft survival was significantly higher in machine perfused kidneys compared
with cold stored kidneys (92.3% vs. 80.2%, P = 0.02). In the present study,
MP preservation clearly reduced the risk of DGF and improved 1-year graft
survival and function in ECD kidneys.
(Current Controlled Trials number: ISRCTN83876362).
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Introduction
As a result of persistent donor organ shortage, kidneys
from expanded criteria donors (ECDs) are nowadays
accepted by many centers and successfully transplanted,
thus shortening waiting times [1–3]. Unfortunately, kid-
neys from ECDs appear to have a higher rate of delayed
graft function (DGF) and a more complicated postopera-
tive course, resulting in an inferior long-term graft sur-
vival overall [2–6]. Although the use of kidneys from
ECDs has an overall risk for graft failure of 1.7, it has also
been shown that transplantation of these kidneys has a
significant survival benefit compared with dialysis treat-
ment [7].
To enhance the outcome of using ECD kidneys, it is
important to analyze the risk factors, including the role
of the preservation method. A recently published system-
atic review suggests that hypothermic machine perfusion
(MP) might be superior compared with simple cold stor-
age (CS), reducing the relative risk of DGF by up to 20%
and increasing 10-year graft survival by 6% [8,9]. How-
ever, this evidence is based on studies that were limited
by an uncontrolled patient selection, small patient num-
bers, the use of different and sometimes out-of-date pres-
ervation solutions, nonstandardized pumping modes and
times, as well as inconsistent application of currently
available pump technology.
We recently reported the overall results of an interna-
tional multi-center randomized trial comparing MP ver-
sus CS in unselected consecutive donors ‡16 years of age,
demonstrating the safety of MP and a significant reduc-
tion in both DGF and 1-year graft loss [10]. As this effect
might be even more pronounced or clinically relevant in
ECD kidneys [2,11], the purpose of this study was to pro-
vide an analysis of the possible effects of MP versus CS
on DGF and early graft survival in ECD kidneys.
Materials and methods
As part of the previously reported multi-center random-
ized trial [10] all consecutively retrieved kidney pairs
from heart-beating deceased ECDs in the Netherlands,
Belgium, and the federal state of North Rhine-Westphalia
in Germany between November 1, 2005 and October 31,
2006 were eligible for randomization. ECDs were defined
according to the United Network of Organ Sharing
(UNOS) definition [1,2], which includes: donor age
‡60 years or 50–60 years with at least two of the follow-
ing criteria: history of hypertension, cerebrovascular cause
of death and serum creatinine 132 lm (1.5 mg/dl) prior
to retrieval.
Donors were only included in the study for analysis if
both organs were transplanted into two different recipi-
ents. Donors accepted for combined organ transplanta-
tion (e.g., liver–kidney transplantation) by the recipient
center were excluded from the trial.
Recipient centers were blinded to the method of preser-
vation (MP or CS) at the time of acceptance of the kid-
ney for a specific recipient.
The study protocol was approved by ethics committees
in each trial region. The study was sponsored by the
Deutsche Forschungsgemeinschaft (DFG TR 811/1-1) and
by Organ Recovery Systems (Itasca, IL, USA).
Randomization and logistics
From each donor, one kidney was randomized to MP
and the contralateral kidney to CS. The randomization
process and logistic management have been described in
an earlier publication [10].
Preservation methods
All kidneys underwent in situ vascular washout with cold
preservation solution (histidine–tryptophan–ketoglutarate
or University of Wisconsin solution). Kidneys assigned to
hypothermic MP were connected to a LifePort Kidney
Transporter (Organ Recovery Systems) shortly after pro-
curement and machine perfused until transplantation. A
pulsatile flow of machine preservation solution (Kidney
Preservation Solution-1; Organ Recovery Systems, Itasca,
IL, USA) at 1–8 C and a fixed systolic perfusion pressure
of 30 mmHg were maintained. The transplant team was
blinded to MP intravascular resistance and flow data.
Kidneys assigned to CS were submerged in preservation
solution and stored on melting ice.
Endpoints and data collection
The primary endpoint of this ECD study was DGF
defined as the need for dialysis during the first week
post-transplant. Secondary endpoints were: functional
delayed graft function (f-DGF), which is defined as the
absence of a decrease in serum creatinine levels of at least
10% per day for at least three consecutive days in the first
week after transplantation [12]; duration of DGF; primary
nonfunction (PNF) of the transplanted kidney; serum cre-
atinine levels at 1–14 days and one, three and 12 months;
creatinine clearance at 1 and 2 weeks and 1, 3 and
12 months; biopsy-proven acute rejection and calcineurin
inhibitor toxicity within the first 2 weeks; recipient hospi-
tal stay length; graft and patient survival; and the number
of biopsy-proven rejection and calcineurin inhibitor tox-
icity episodes up to 1 year post-transplant.
In addition, standard donor and recipient data and the
type of induction immunosuppression therapy were
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recorded. Follow-up data were collected in a secure online
database hosted by Eurotransplant and were provided by
each of the 60 participating transplant centers.
Statistics
The analysis was powered to detect a reduction in DGF
of at least 20% based on the assumption of a 40% inci-
dence of DGF in recipients with kidneys preserved by CS.
With a power of 0.8 and a type I error of 0.05, the
required sample size was 82 pairs of ECD kidneys. The
primary analysis of the DGF endpoint consisted of a
logistic regression model with the covariates shown in
Table 3.
Secondary endpoint variables were assessed for univari-
ate differences between groups by the McNemar or the
Wilcoxon signed rank test. Differences between survival
curves were determined by the log rank test. A Cox pro-
portional hazards model was applied to examine which
variables significantly influenced the risk of graft failure.
All P-values are two-sided and not adjusted for multiple
testing. Analyses were conducted using spss (IBM Cor-
poration, Somer, NY, USA), sas (SAS Institute Inc., Cary,
NC, USA) and r software packages (The R Foundation
for Statistical Computing, Vienna, Austria).
Results
Between November 1, 2005 and October 31, 2006, 336
out of 654 deceased donors 16 years of age and older
were included in the overall study. Of these 654 donors,
200 were ECDs. There were 109 ECDs who were not
studied, thus 91 donors were included in the subgroup
analysis. The reasons for exclusion are described in
Table 1. The main reason was that one or both kidneys
were not transplantable (42/109). Preservation methods
were switched in five donors. In two cases this was attrib-
utable to aberrant vascular anatomy, whereas in three
cases no reason could be found.
Donor and recipient characteristics are summarized in
Table 2. The median donor age was 66 years (50–81 years)
and the median recipient age was 65 years in both groups.
There were no significant differences between the two
groups concerning relevant baseline characteristics.
Further subset analysis showed no differences concern-
ing median cold ischemia time between MP and CS for
donors older than 65 years (9 h vs. 10 h, P = 0.61) or the
subset of transplants with more than three HLA mis-
matches (10 h vs. 10 h, P = 0.92).
In this ECD subgroup, DGF occurred in 27 patients in
the CS group (29.7%) and in 20 patients in the MP
group (22%). This difference was not statistically signifi-
cant in the univariate analysis (P = 0.27) (Table 2). The
analysis using the logistic regression model showed that
MP significantly reduced the risk of DGF compared with
CS (adjusted odds ratio 0.460, P = 0.047) (Table 3).
The number of kidney pairs from the same donor for
which both kidneys developed DGF after transplantation
was nine.
There was no significant difference in the incidence of
DGF in the ECD subgroup compared with the main data
[10] set in neither machine perfused kidneys (22% vs.
20.8%) nor in cold stored kidneys (29.7% vs. 26.5%).
Further significant factors affecting the risk for DGF were
cold ischemia time, duration of pretransplant dialysis,
and whether it was a retransplant versus a first transplant.
Secondary endpoints
The incidence of PNF in the CS group (12%) was four
times higher than in the MP group (3%) (P = 0.04). Of
the cold stored kidneys with PNF in the main dataset,
68% were from ECDs; however, only 42.5% of machine
perfused kidneys with PNF came from ECDs (P = 0.52).
The PNF in cold stored ECD kidneys was significantly
more frequent than in the whole group of cold stored
kidneys (P = 0.025), whereas there was no difference in
the occurrence of PNF in the machine perfused kidneys
when ECDs were compared with all donors. The inci-
dence of f-DGF was 29.7% after CS and 20.8% after MP
(P = 0.31) (Table 2).
There were no significant differences between the two
groups concerning creatinine clearance up to 3 months,
daily creatinine values up to day 14, the incidence of
biopsy-proven calcineurin inhibitor toxicity, acute rejec-
tion episodes, and the length of hospital stay. Creatinine
clearance after 1 year was significantly higher in the MP
group compared with the CS group (78 ± 41 ml/min vs.
69 ± 48 ml/min, P = 0.01) (Table 2).
Table 1. Reasons for exclusion of donors.
Reported after procurement 1
Could not be reached in time 8
Donor center refusal 0
Donor family refusal 0
Donor procedure canceled 5
One or both kidneys not transplantable 42
Combined organ offer 7
Other reasons 32
Kidney rejected at transplant center 4
Technical failure MP 2
Not assessed by mistake 0
Unknown 8
Potential donors N = 200.
Donors included N = 91.
Reasons for excluding N = 109.
MP, machine perfusion.
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Patient and graft survival
No patient deaths occurred in the first 14 days after
transplantation. Patient survival after 1 year was 93.4% in
the MP group and 96.7% in the CS group (P = 0.30).
One-year death censored graft survival was significantly
higher in machine perfused kidneys compared with cold
stored kidneys (92.3% vs. 80.2%, P = 0.02) (Fig. 1a). This
difference was even more pronounced if DGF had
occurred. Although in the MP group there was a differ-
ence of nearly 10% for 1-year graft survival if DGF
occurred compared with kidneys with immediate func-
tion, this difference was not statistically significant (94%
vs. 85%, P = 0.164). In the CS group, graft survival was
impressively reduced if DGF occurred (41% vs. 97%,
P < 0.0001). If only recipients of grafts that developed
DGF were analyzed, there was a significant difference in
1-year graft survival between machine perfused kidneys
and cold stored kidneys (85% vs. 41%, P = 0.003)
(Fig. 1b).
Cox regression analysis showed that MP significantly
reduced the risk of graft failure in the first year with a
hazard ratio of 0.353 (P = 0.022) (Table 4). As a relevant
Table 2. Donor and recipient characteristics, results of univariate analysis.
MP arm CS arm P-value
Donor
Age (years) 66 (50–81)
Gender M/F (49/42)
BMI 27 (21–42)











Age (years) 65 (20–79) 65 (32–79) 0.75
Gender: M/F 55/36 57/34 0.88
Pre-RTX dialysis duration (days) 1728 (149–3866) 1728 (137–5154) 0.68
Previous transplants 0/1/2 (69/19/3) 0/1/2/3 (64/19/6/2) 0.29
Current PRA (%) 0–5/6–84/85+ (85/5/1) 0–5/6–84/85+ (81/9/1) 0.43
HLA-A, -B, -DR mismatches (% of 0 MM) 12.1 8.8 0.63
CIT (h) 13 (3–23) 13 (4–29) 0.97
Endpoints
DGF, Y/N (%) 20/71 (22) 27/64 (29.7) 0.27
Duration of DGF (median, days) 14 (3–31) 15 (4–41) 0.45
Duration of DGF <7 days, Y/N (%) 5/15 (33.3) 4/23 (17.4) 0.22
f-DGF, Y/N (%) 15/57 (20.8) 22/52 (29.7) 0.31
PNF, Y/N (%) 3/88 (3) 11/80 (12) 0.04
CNI intoxicity, Yes/No/U (%) 5/78/8 3/81/7 0.63
Acute graft rejection, Yes/No/U (%) 17/64/10 16/67/8 0.98
Creatinine clearance at 1 year (mean ± SD ml/min) 78 ± 41 69 ± 48 0.01
CS, cold storage; DGF, delayed graft function; MP, machine perfusion; PNF, primary nonfunction; CIT, cold ischemia time; HTK, histidine–trypto-
phan–ketoglutarate; UW, University of Wisconsin solution; MM, mismatch; PRA, panel reactive antibodies.
Table 3. Logistic regression model – dependent variable delayed
graft function (DGF).
Odds ratio (95% CI) P-value
Treatment arm MP versus CS 0.460 (0.213–0.989) 0.047
CIT 1.151 (1.057–1.254) 0.001
HLA MM 1.905 (0.454–8.000) 0.379
Recent PRA 1.004 (0.980–1.029) 0.742
Recipient age 1.586 (0.569–4.424) 0.378
Donor age 1.036 (0.957–1.122) 0.385
First/re-transplant 2.307 (1.257–4.234) 0.007
Duration of pretransplant dialysis 1.001 (1.000–1.001) 0.021
CIT, cold ischemia time; CS, cold storage; MP, machine perfusion;
MM, mismatch; PRA, panel reactive antibodies.
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defining factor for ECDs, donor age had no significant
influence on DGF in this analysis. However, even in this
older group of donors, it did significantly influence 1-year
graft survival (hazard ratio 1.103, P = 0.016).
Discussion
In the context of this randomized trial [10] we have now
focused on the effect of MP in kidneys from ECDs. This
effect was even more pronounced than in the overall
study, with an odds ratio (OR) of 0.46 for the risk of
developing DGF (overall OR of 0.57). Nevertheless, direct
comparison of the treatment effects on DGF between
expanded criteria donation and standard criteria donation
that also included deceased donation after cardiac death
showed no significant difference.
It is interesting to see that in this study, the incidence
of DGF in ECD kidneys is only slightly higher than in the
main data set, irrespective of the preservation method.
The incidence of DGF found in this trial is clearly lower
than that reported in previous studies using ECD [13,14].
One explanation for this might be the relatively short
cold ischemic times in this study.
The hazard ratio for graft failure was also more
reduced for ECDs with a value of 0.35 than in the overall
study with 0.52. The number of recipients receiving an
ECD kidney with PNF was fourfold higher in the CS
group compared with the MP group. Such early graft fail-
ure, in addition to subsequent graft failures, puts a severe
burden on patients and waiting lists for kidney transplan-
tation. The effect we observed was much stronger than
described in a recent meta-analysis [8].
For ECDs, we also show for the first time that at 1 year
post-transplant, the function of the surviving grafts was
better if the kidney was preserved by MP compared with
CS. These results differ from retrospective studies as these
studies show only short term beneficial effects of MP with
a reduction of DGF but no improvement in graft survival
[15–17].
Although donor age is already part of the ECD defini-
tion, it was the only significant predictive factor in the
Cox proportional hazard model for graft survival after
1 year, apart from the treatment modality MP versus CS
(Table 4).
The effect of MP on the reduction in serum creatinine
levels in the first 14 days compared with cold stored kid-
neys could not be demonstrated in the ECD group,
although, this was shown in the main data set. This is
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Figure 1 (a) Post-transplant graft survival rates. All consecutive renal
transplants from heart beating (HB) expanded criteria donor (ECD)
N = 182. Logrank test of equality machine perfusion (MP) versus cold
storage (CS) P = 0.02. (b) Post-transplant graft survival rates. All con-
secutive renal transplants from HB ECD N = 182 – Logrank test of
equality. Within CS group delayed graft function (DGF) versus no DGF
P < 0.0001. Within MP group DGF versus no DGF P = 0.164. Within
no DGF group MP versus CS P = 0.48. Within DGF group MP versus
CS P = 0.003.
Table 4. Cox ‘proportional hazards model’ – dependent variable
1 year graft function.
Hazards ratio (95% CI) P-value
Treatment arm MP versus CS 0.353 (0.145–0.862) 0.022
CIT 1.082 (0.994–1.179) 0.068
HLA MM 4.070 (0.484–34.208) 0.196
Recent PRA 1.006 (0.983–1.030) 0.600
Recipient age 0.629 (0.219–1.805) 0.388
Donor age 1.103 (1.018–1.195) 0.016
First/re-transplant 0.938 (0.480–1.832) 0.851
Duration of pretransplant dialysis 1.000 (1.000–1.001) 0.495
CIT, cold ischemia time; CS, cold storage; MP, machine perfusion;
MM, mismatch; PRA, panel reactive antibodies.
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The f-DGF was chosen instead of creatinine reduction
ratio (CRR) since the CRR only takes into account days 1
and 2 post-transplant. The f-DGF has a scope of 7 days
after Tx and has also been validated by Boom et al [12].
The scope of the classical DGF definition (in terms of
hemodialysis requirement) is also 1 week, so in our view
f-DGF is a more functional definition which uses the
same time frame.
Parameters characterizing the individual kidney during
perfusion – such as vascular resistance, and flow and per-
fusate viability markers – were not used as potential pre-
dictors of outcome. In a separate analysis, renal
resistances during MP were shown to correlate with DGF
and 1 year graft survival (univariate analysis), but not
with PNF [18]. Hence, further analysis of these parame-
ters and perfusate biomarkers might help to identify kid-
neys at risk for DGF and PNF, also recently shown in an
experimental study [19–21]. Interestingly, but not fully
analyzed yet, was that kidneys with DGF after MP and
after CS were seldom from the same donor in this study.
This could imply that parameters of MP providing a
prognosis for the development of DGF in the perfused
kidney will in most cases not help to identify renal grafts
at risk for DGF after CS.
A striking fact is that the proportion of ECDs in Ger-
many, where donation is only allowed after brain death,
is almost 50% (47.7% in 2006 and 48.2% in 2007) (Euro-
transplant analysis). The proportion of ECDs in the main
study was 27.9% (94/336) when donation after cardiocir-
culatory death was included and 30.9% (91/294) when
only donation after brain death was considered. This rela-
tively small proportion of ECDs is an effect caused by the
procurement policy in Belgium and the Netherlands and
could imply a strong bias toward better-quality ECD cate-
gorized donors in the present study. It can be assumed
that ECD populations in other countries are not fully
comparable to our study’s inclusions and, therefore, the
effect of MP versus CS as described in this article could
be somewhat different.
The high rate of exclusion could represent a possible
bias, but is explained by the early randomization process
and high exclusion rate because one or both kidneys were
eventually not transplanted. Exclusion for a combined
organ transplantation was rare. This too could provide a
bias toward the ‘better’ extended criteria donor, and per-
haps effects of MP could be even more pronounced in a
series with more marginal ECD kidneys.
There were no kidney pairs that could not be random-
ized. All consecutive ECD donor kidney pairs were
assessed for inclusion, randomized if they met the initial
inclusion criteria, and only if vascular anatomy of the kid-
ney randomized for MP prevented a reliable connection
of the kidney to the perfusion machine, could the preser-
vation methods for this pair be switched, thus indeed
frustrating randomization. We checked whether the pres-
ence of vascular anomalies had any relevant influence on
post-transplant outcome, and this was not the case.
Therefore, the few cases in which preservation methods
were switched did not introduce any bias to our results.
The recent review of Yuan et al. critically describes the
possibilities and developments in the field of MP over the
last decades. The authors emphasize the importance
investigating the relevance of MP for marginal donor
organs. We feel that the present study adds important
new data which support the benefit of MP for the preser-
vation of such donor organs [22].
In summary, this study shows that MP reduces the risk
of DGF and improves 1-year graft survival and function
in ECD kidneys. The development of better pretransplant
predictors for DGF [23] could increase the cost-effective-
ness of MP in extended criteria donation. We believe that
as long as there are no such reliable predictors, every
ECD kidney should be machine perfused, because in the
first year after transplantation alone, 12% more grafts
could be saved as a result of MP.
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